brl-28500 has been researched along with Bacteremia* in 3 studies
1 trial(s) available for brl-28500 and Bacteremia
Article | Year |
---|---|
Ticarcillin/clavulanate for the treatment of serious infections in hospitalized pediatric patients.
Topics: Bacteremia; Child; Child, Preschool; Clavulanic Acids; Cross Infection; Drug Therapy, Combination; Female; Hospitalization; Humans; Infant; Infant, Newborn; Male; Prognosis; Severity of Illness Index; Ticarcillin; Treatment Outcome | 1998 |
2 other study(ies) available for brl-28500 and Bacteremia
Article | Year |
---|---|
Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients.
The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia.. In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed.. SXT+LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT+TIM showed synergy in 71, and no interactions in 18. SXT+MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT+fluoroquinolone was not associated with improved prognosis compared with monotherapy.. The in vitro data indicated that SXT+TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT+fluoroquinolone combination therapy for S. maltophilia infection. Topics: Aged; Anti-Bacterial Agents; Bacteremia; Clavulanic Acids; Drug Therapy, Combination; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Male; Middle Aged; Minocycline; Neoplasms; Stenotrophomonas maltophilia; Ticarcillin; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2017 |
Beware of short-course therapy for Staphylococcus aureus bacteremia without a removable cause.
Staphylococcus aureus bacteremia has long been known to cause significant morbidity and mortality. The optimal treatment of this disease has evolved over the years. Recently, criteria have been established for the use of shorter courses of antibiotic therapy in certain patients, most notably those with an easily removed source of the bacteremia. We present the case of a 55-year-old man with S aureus bacteremia unrelated to an intravascular device. He was treated with "short-course" antibiotic therapy, and lumbar diskitis and an epidural abscess developed. Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Cefazolin; Cephalosporins; Clavulanic Acids; Discitis; Drug Therapy, Combination; Enzyme Inhibitors; Epidural Abscess; Follow-Up Studies; Foot Diseases; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteomyelitis; Staphylococcal Infections; Staphylococcus aureus; Ticarcillin; Vancomycin | 2000 |